metoprolol has been researched along with Skin Neoplasms in 3 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
Skin Neoplasms: Tumors or cancer of the SKIN.
Excerpt | Relevance | Reference |
---|---|---|
"Pseudo-Sezary syndrome is a benign lymphoproliferative disorder, which clinically and pathologically mimics true Sezary syndrome." | 2.52 | Drug-induced pseudo-Sezary syndrome: a case report and literature review. ( Reeder, MJ; Wood, GS, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 2 (66.67) | 2.80 |
Authors | Studies |
---|---|
Chang, Q | 1 |
Long, J | 1 |
Hu, L | 1 |
Chen, Z | 1 |
Li, Q | 1 |
Hu, G | 1 |
Tchernev, G | 1 |
Reeder, MJ | 1 |
Wood, GS | 1 |
1 review available for metoprolol and Skin Neoplasms
Article | Year |
---|---|
Drug-induced pseudo-Sezary syndrome: a case report and literature review.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 2015 |
2 other studies available for metoprolol and Skin Neoplasms
Article | Year |
---|---|
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Dose-Response Relationship, Dru | 2020 |
THE NITROSAMINE CONTAMINATION IN BETA BLOCKERS (BISOPROLOL/METOPROLOL), ACE INHIBITORS (LISINOPRIL/PERINDOPRIL), THIAZIDES DIURETICS (HCT), CALCIUM CHANNEL BLOCKERS (AMLODIPINE/FELODIPINE), SARTANS (CANDESARTAN) AND ТHE SUBSEQUENT SKIN CANCER DEVELOPMENT
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antih | 2023 |